What is Leerink Partnrs' Estimate for JAZZ FY2024 Earnings?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) - Equities researchers at Leerink Partnrs raised their FY2024 EPS estimates for shares of Jazz Pharmaceuticals in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the specialty pharmaceutical company will earn $16.57 per share for the year, up from their prior forecast of $16.47. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $16.95 per share.

Several other analysts also recently weighed in on JAZZ. HC Wainwright restated a "buy" rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Needham & Company LLC restated a "buy" rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Morgan Stanley raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Royal Bank of Canada reissued an "outperform" rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $177.00.

Jazz Pharmaceuticals Stock Up 0.7 %

NASDAQ:JAZZ traded up $0.84 during mid-day trading on Thursday, hitting $125.11. 300,151 shares of the company's stock were exchanged, compared to its average volume of 486,591. The company has a market cap of $7.56 billion, a PE ratio of 17.62, a P/E/G ratio of 0.87 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $134.17. The business has a fifty day moving average price of $122.74 and a 200 day moving average price of $115.76.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,253 shares of company stock worth $1,001,434 in the last 90 days. 4.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Wedge Capital Management L L P NC bought a new stake in Jazz Pharmaceuticals during the third quarter worth approximately $32,497,000. Pacer Advisors Inc. increased its position in shares of Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock valued at $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Cinctive Capital Management LP bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after buying an additional 100,112 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in shares of Jazz Pharmaceuticals by 47.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 268,783 shares of the specialty pharmaceutical company's stock worth $29,945,000 after purchasing an additional 86,768 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.